Recent advancements in CML treatment have brought to light the limitations of strategies focused solely on BCR::ABL1-dependent mechanisms in patients with CML resistant to TKIs [15]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.